Facing Tougher Competition At Home, China's Mindray Should Target Global Mid- To High-end Market, Analysts Say
Facing a new round of marketing campaigns from international device makers targeting China's low- to mid-end hospital markets, Shenzhen based Mindray Medical will be better off focusing instead on mid- to high-end global markets to stay competitive, analysts say
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
Entries for the Scrip Awards are now open. Now in their 21st year, the Awards seek to reward the outstanding achievements of the pharmaceutical, biotech and allied industries in improving human health.
Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.
AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.